Icad Inc (ICAD) 7.46 $ICAD
39.0% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Thu May 08, 9:37AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 39.04% as of today's recent price of $7.02.
Nasdaq stocks posting largest percentage decreases
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
iCAD Reports First Quarter Financial Results
Business Wire - Tue May 06, 3:07PM CDT
--Conference Call Begins Today at 5:00 p.m. Eastern Time
iCAD to Host First Quarter 2014 Financial Results Conference Call on Tuesday, May 6, 2014
Business Wire - Mon May 05, 5:00AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three months ended March 31, 2014, following the close of the market on Tuesday, May 6, 2014.
Icad Down 24.6% Since SmarTrend Downtrend Call (ICAD)
Comtex SmarTrend(R) - Thu May 01, 9:11AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 24.62% as of today's recent price of $8.68.
iCAD and Deerfield Agree to Terminate the Revenue-Sharing Component of Debt Facility, Deerfield Exercises Warrants
Business Wire - Mon Apr 28, 3:00PM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported that the Company has entered into an agreement effective April 28, 2014 that terminates the revenue-sharing component of iCAD's debt facility agreement with Deerfield Management Company LP, dated December 29, 2011, in exchange for a cash payment of $4.1 million to Deerfield. Under this portion of the debt facility, iCAD historically paid Deerfield an average of 4.0% of revenues, which had an annual cash cost to iCAD of approximately $1.3 million in fiscal year 2013. Additionally, the Company has amended the facility agreement to eliminate the Company's ability to extend the final payment date for a year.
Icad Has Returned 27.1% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Apr 23, 9:15AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 27.05% as of today's recent price of $8.40.
iCAD Reports Continued Growth in Adoption and Utilization of Its Xoft System to Treat Skin Cancer
Business Wire - Thu Apr 17, 2:55PM CDT
iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced that more than 4,000 non-melanoma skin cancer (NMSC) patients have been treated using the Xoft(R) Axxent(R) Electronic Brachytherapy System(R) demonstrating continued growth and utilization of the system among radiation oncologists and dermatologists. In addition, a growing body of clinical evidence provides ongoing support for the use of the Xoft System for this skin cancer application. The Xoft System offers an alternative, pain-free treatment option for patients who may not be candidates for surgery or who are concerned with cosmetic outcomes associated with surgery. The Xoft System is the only electronic brachytherapy (eBx (R)) system with peer-reviewed published data in support of this application.
27.7% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Tue Apr 15, 4:56PM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 27.75% as of today's recent price of $8.32.
Icad Shares Down 29.1% Since SmarTrend's Sell Call (ICAD)
Comtex SmarTrend(R) - Tue Apr 08, 11:04AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 29.14% as of today's recent price of $8.16.
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors.
Downtrend Call Working As Icad Stock Falls 16.9% (ICAD)
Comtex SmarTrend(R) - Tue Apr 01, 9:48AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 16.89% as of today's recent price of $9.57.
Icad Has Returned 15.6% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Tue Mar 25, 9:26AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 15.59% as of today's recent price of $9.72.
iCAD, Inc. Announces Closing of Underwritten Public Offering of Common Stock
Business Wire - Mon Mar 17, 1:25PM CDT
iCAD, Inc. ("iCAD"
(NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has closed its previously-announced registered firm commitment underwritten public offering of 2,760,000 shares at a price to the public of $11.00 per share. The number of shares sold in the offering includes the underwriter's full exercise of the over-allotment option to purchase 360,000 common shares. iCAD estimates net proceeds from the offering to be approximately $28.2 million, after deducting underwriting discounts and estimated offering expenses. iCAD intends to use the proceeds from the offering for working capital and other general corporate purposes.
Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
iCAD, Inc. Announces Pricing of 2,400,000 Share Public Offering of Common Stock
Business Wire - Wed Mar 12, 6:00AM CDT
iCAD, Inc. ("iCAD" (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 360,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about March 17, 2014, subject to satisfaction of closing conditions.
iCAD Announces More Than 1,000 Early Stage Breast Cancer Patients Treated with Intraoperative Radiation Therapy (IORT) Using the Xoft System
Business Wire - Thu Mar 06, 8:20AM CST
iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis and radiation therapy solutions for the early identification and treatment of cancer, today announced at the 31st Annual Miami Breast Cancer Conference that more than 1,000 early stage breast cancer patients have been treated with Intraoperative Radiation Therapy (IORT) using the Xoft(R) Axxent(R) Electronic Brachytherapy System(R). With IORT, a full course of radiation therapy is delivered to the patient in the operating room immediately following lumpectomy, replacing six to eight weeks of daily traditional radiation.
iCAD, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Wed Mar 05, 3:05PM CST
iCAD, Inc. ("iCAD" (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced that it intends to offer 2,000,000 shares of its common stock in a firm commitment underwritten public offering, subject to market and other conditions. In addition, iCAD intends to grant the underwriter a 30-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any.
iCAD Appoints Dr. Robert Goodman to Board of Directors
Business Wire - Mon Feb 24, 8:04AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Robert Goodman, M.D., has been named to iCAD's Board of Directors. Dr. Goodman brings nearly 50 years of clinical experience, along with extensive academic and leadership credentials. He is the first radiation oncologist to serve on iCAD's multidisciplinary Board.
iCAD to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Fri Feb 21, 2:50PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Company management will participate in the 2014 RBC Capital Markets' Global Healthcare Conference taking place from February 25-26, 2014 at the New York Palace Hotel.
39.0% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Thu May 08, 9:37AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 39.04% as of today's recent price of $7.02.
Nasdaq stocks posting largest percentage decreases
AP - Wed May 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
iCAD Reports First Quarter Financial Results
Business Wire - Tue May 06, 3:07PM CDT
--Conference Call Begins Today at 5:00 p.m. Eastern Time
iCAD to Host First Quarter 2014 Financial Results Conference Call on Tuesday, May 6, 2014
Business Wire - Mon May 05, 5:00AM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three months ended March 31, 2014, following the close of the market on Tuesday, May 6, 2014.
Icad Down 24.6% Since SmarTrend Downtrend Call (ICAD)
Comtex SmarTrend(R) - Thu May 01, 9:11AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 24.62% as of today's recent price of $8.68.
iCAD and Deerfield Agree to Terminate the Revenue-Sharing Component of Debt Facility, Deerfield Exercises Warrants
Business Wire - Mon Apr 28, 3:00PM CDT
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported that the Company has entered into an agreement effective April 28, 2014 that terminates the revenue-sharing component of iCAD's debt facility agreement with Deerfield Management Company LP, dated December 29, 2011, in exchange for a cash payment of $4.1 million to Deerfield. Under this portion of the debt facility, iCAD historically paid Deerfield an average of 4.0% of revenues, which had an annual cash cost to iCAD of approximately $1.3 million in fiscal year 2013. Additionally, the Company has amended the facility agreement to eliminate the Company's ability to extend the final payment date for a year.
Icad Has Returned 27.1% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Wed Apr 23, 9:15AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 27.05% as of today's recent price of $8.40.
iCAD Reports Continued Growth in Adoption and Utilization of Its Xoft System to Treat Skin Cancer
Business Wire - Thu Apr 17, 2:55PM CDT
iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced that more than 4,000 non-melanoma skin cancer (NMSC) patients have been treated using the Xoft(R) Axxent(R) Electronic Brachytherapy System(R) demonstrating continued growth and utilization of the system among radiation oncologists and dermatologists. In addition, a growing body of clinical evidence provides ongoing support for the use of the Xoft System for this skin cancer application. The Xoft System offers an alternative, pain-free treatment option for patients who may not be candidates for surgery or who are concerned with cosmetic outcomes associated with surgery. The Xoft System is the only electronic brachytherapy (eBx (R)) system with peer-reviewed published data in support of this application.
27.7% Return Seen to Date on SmarTrend Icad Call (ICAD)
Comtex SmarTrend(R) - Tue Apr 15, 4:56PM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 3 months, Icad has returned 27.75% as of today's recent price of $8.32.
Icad Shares Down 29.1% Since SmarTrend's Sell Call (ICAD)
Comtex SmarTrend(R) - Tue Apr 08, 11:04AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 29.14% as of today's recent price of $8.16.
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors.
Downtrend Call Working As Icad Stock Falls 16.9% (ICAD)
Comtex SmarTrend(R) - Tue Apr 01, 9:48AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 16.89% as of today's recent price of $9.57.
Icad Has Returned 15.6% Since SmarTrend Recommendation (ICAD)
Comtex SmarTrend(R) - Tue Mar 25, 9:26AM CDT
SmarTrend identified a Downtrend for Icad (NASDAQ:ICAD) on January 27th, 2014 at $11.52. In approximately 2 months, Icad has returned 15.59% as of today's recent price of $9.72.
iCAD, Inc. Announces Closing of Underwritten Public Offering of Common Stock
Business Wire - Mon Mar 17, 1:25PM CDT
iCAD, Inc. ("iCAD"
(NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has closed its previously-announced registered firm commitment underwritten public offering of 2,760,000 shares at a price to the public of $11.00 per share. The number of shares sold in the offering includes the underwriter's full exercise of the over-allotment option to purchase 360,000 common shares. iCAD estimates net proceeds from the offering to be approximately $28.2 million, after deducting underwriting discounts and estimated offering expenses. iCAD intends to use the proceeds from the offering for working capital and other general corporate purposes. Nasdaq stocks posting largest volume increases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
iCAD, Inc. Announces Pricing of 2,400,000 Share Public Offering of Common Stock
Business Wire - Wed Mar 12, 6:00AM CDT
iCAD, Inc. ("iCAD"
(NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 360,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about March 17, 2014, subject to satisfaction of closing conditions. iCAD Announces More Than 1,000 Early Stage Breast Cancer Patients Treated with Intraoperative Radiation Therapy (IORT) Using the Xoft System
Business Wire - Thu Mar 06, 8:20AM CST
iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis and radiation therapy solutions for the early identification and treatment of cancer, today announced at the 31st Annual Miami Breast Cancer Conference that more than 1,000 early stage breast cancer patients have been treated with Intraoperative Radiation Therapy (IORT) using the Xoft(R) Axxent(R) Electronic Brachytherapy System(R). With IORT, a full course of radiation therapy is delivered to the patient in the operating room immediately following lumpectomy, replacing six to eight weeks of daily traditional radiation.
iCAD, Inc. Announces Proposed Public Offering of Common Stock
Business Wire - Wed Mar 05, 3:05PM CST
iCAD, Inc. ("iCAD"
(NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced that it intends to offer 2,000,000 shares of its common stock in a firm commitment underwritten public offering, subject to market and other conditions. In addition, iCAD intends to grant the underwriter a 30-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. iCAD Appoints Dr. Robert Goodman to Board of Directors
Business Wire - Mon Feb 24, 8:04AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Robert Goodman, M.D., has been named to iCAD's Board of Directors. Dr. Goodman brings nearly 50 years of clinical experience, along with extensive academic and leadership credentials. He is the first radiation oncologist to serve on iCAD's multidisciplinary Board.
iCAD to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
Business Wire - Fri Feb 21, 2:50PM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Company management will participate in the 2014 RBC Capital Markets' Global Healthcare Conference taking place from February 25-26, 2014 at the New York Palace Hotel.
